The incidence of all-cause, cardiovascular and respiratory disease admission among 20,252 users of lisinopril vs. perindopril: A cohort study

Wong, Martin C. S.; Chan, David W.; Wang, Haoxiang; Tam, Wilson W.S.; Cheung, Clement S.K.; Yan, Bryan P.; Coats, Andrew J.S.

doi:10.1016/j.ijcard.2016.06.053

Cited by 4 publications

(3 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This effect should contribute to the improvement of cardiovascular prognosis. Moreover, lisinopril users were signifi cantly more likely to be admitted due to respiratory diseases, renal diseases, diabetes and all causes at 24 months than perindopril users (23,24), suggesting different ACE inhibitors U n c o r r e c t e d might have a different incidence of hospital admissions (24). These intra-class differences of ACE inhibitors could be considered by clinical guidelines when the preferred fi rst-line antihypertensive drugs are recommended (23).…”

Section: U N C O R R E C T E Dmentioning

confidence: 99%

“…Moreover, lisinopril users were signifi cantly more likely to be admitted due to respiratory diseases, renal diseases, diabetes and all causes at 24 months than perindopril users (23,24), suggesting different ACE inhibitors U n c o r r e c t e d might have a different incidence of hospital admissions (24). These intra-class differences of ACE inhibitors could be considered by clinical guidelines when the preferred fi rst-line antihypertensive drugs are recommended (23). Notably, both baseline clinical phenotype and genotype determine the effi cacy of widely prescribed ACE inhibitor in stable coronary artery disease (CAD) (25).…”

Section: U N C O R R E C T E Dmentioning

confidence: 99%

See 1 more Smart Citation

Antihypertensive effect of telmisartan versus perindopril in hypertensive patients

Zhao¹,

Liu²,

CHEN³

et al. 2023

BLL

View full text Add to dashboard Cite

OBJECTIVE: We performed this meta-analysis determining the antihypertensive effect of telmisartan versus perindopril in patients with essential hypertension. BACKGROUND: The comparison of antihypertensive effects between telmisartan and perindopril were controversial. METHODS: Pubmed, Web of Science, and Cochrane Central were searched for all published studies. RESULTS: The antihypertensive effects were assessed in 753 patients included in 7 trials with a mean follow-up of 20 ± 16 weeks. There was no signifi cant difference between telmisartan and perindopril in reduction of systolic blood pressure (SBP, weighted mean differences (WMD) 0.02 (95% confi dence interval (CI), -2.78, 2.81) mmHg, p > 0.05). The reduction of diastolic BP (DBP) treated with telmisartan was greater than perindopril in these patients (WMD -2.05 (95% CI, -2.60, -1.49) mm Hg, p < 0.001). Considering the effects of different doses on BP reduction, a sub-analysis was performed. The reduction of DBP treated with 40 mg/day telmisartan was greater than 4-5 mg/day perindopril (WMD -2.18 (95% CI, -2.83, -1.53) mmHg, p < 0.001). There was no difference for SBP reduction treated with 40 mg/day telmisartan or 4-5 mg/day perindopril (p > 0.05). CONCLUSION: The reduction of DBP is greater treated with telmisartan than perindopril in patients with essential hypertension (Tab. 2, Fig. 4, Ref. 34).

show abstract

Section: U N C O R R E C T E Dmentioning

confidence: 99%

Section: U N C O R R E C T E Dmentioning

confidence: 99%

Antihypertensive effect of telmisartan versus perindopril in hypertensive patients

Zhao¹,

Liu²,

CHEN³

et al. 2023

BLL

View full text Add to dashboard Cite

show abstract

“…A third group of drugs composed of phosphorus-containing ACE inhibitors is represented by fosinopril [145, 146]. Although direct ACE inhibitors comparisons among the available agents are rare, lisinopril, perindopril, and quinapril may be favored because of their prolonged half-life and greater lipophilicity [147]. As reviewed elsewhere [18], evidence from large clinical trials document a beneficial effect of ACE inhibitors in retarding HF progression and repeat hospitalizations, adverse cardiac remodeling and increased survival post myocardial infarction, vascular disease secondary to atherosclerosis or hypertension, and chronic renal disease including diabetic nephropathy.…”

Section: 0 Angiotensin Converting Enzyme Inhibitorsmentioning

confidence: 99%

Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease

Ferrario

Mullick

2017

Pharmacological Research

102

View full text Add to dashboard Cite

A collective century of discoveries establishes the importance of the renin angiotensin aldosterone system in maintaining blood pressure, fluid volume and electrolyte homeostasis via autocrine, paracrine and endocrine signaling. While research continues to yield new functions of angiotensin II and angiotensin-(1-7), the gap between basic research and clinical application of these new findings is widening. As data accumulates on the efficacy of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers as drugs of fundamental importance in the treatment of cardiovascular and renal disorders, it is becoming apparent that the achieved clinical benefits is suboptimal and surprisingly no different than what can be achieved with other therapeutic interventions. We discuss this issue and summarize new pathways and mechanisms effecting the synthesis and actions of angiotensin II. The presence of renin-independent non-canonical pathways for angiotensin II production are largely unaffected by agents inhibiting renin angiotensin system activity. Hence, new efforts should be directed to develop drugs that can effectively block the synthesis and/or action of intracellular angiotensin II. Improved drug penetration into cardiac or renal sites of disease, inhibiting chymase –the primary angiotensin II forming enzyme in the human heart–, and/or inhibiting angiotensinogen synthesis would all be more effective strategies to inhibit the system. Additionally, given the role of angiotensin II in the maintenance of renal homeostatic mechanisms, any new inhibitor should possess greater selectivity of targeting pathogenic angiotensin II signaling processes and thereby limit inappropriate inhibition.

show abstract

The Role of Renin–Angiotensin–Aldosterone System and Its New Components in Arterial Stiffness and Vascular Aging

Neves

Cunha

et al. 2018

High Blood Press Cardiovasc Prev

View full text Add to dashboard Cite

Many cardiovascular diseases present renin-angiotensin-aldosterone system (RAAS) hyperactivity as an important pathophysiological mechanism to be target in the therapeutic approaches. Moreover, arterial stiffness is currently considered as a new independent risk factor for cardiovascular disease in different clinical conditions, including hypertension and chronic kidney disease. In fact, excessive stimulation of angiotensin type 1 (AT1) receptors, as well as mineralocorticoid receptors, results in cellular growth, oxidative stress and vascular inflammation, which may lead to arterial stiffness and accelerate the process of vascular aging. In the last decades, a vasoprotective axis of the RAAS has been discovered, and now it is well established that new components with antioxidant and anti-inflammatory properties play important roles promoting vasodilation, natriuresis and reducing collagen deposition, thus attenuating arterial stiffness and improving endothelial function. In this review, we will focus on these pathophysiological mechanisms and the relevance of RAAS inhibition by different strategies to increase arterial compliance and to decelerate vascular aging.

show abstract

The incidence of all-cause, cardiovascular and respiratory disease admission among 20,252 users of lisinopril vs. perindopril: A cohort study

Abstract: These findings support intra-class differences in the effectiveness of ACEIs, which could be considered by clinical guidelines when the preferred first-line antihypertensive drugs are recommended.

Cited by 4 publications

References 38 publications

Antihypertensive effect of telmisartan versus perindopril in hypertensive patients

Antihypertensive effect of telmisartan versus perindopril in hypertensive patients

Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease

The Role of Renin–Angiotensin–Aldosterone System and Its New Components in Arterial Stiffness and Vascular Aging

Contact Info

Product

Resources

About